The facility underwent an inspection from April 21 to April 25, 2025. The inspection has been classified as Voluntary Action Indicated (VAI), with the FDA confirming the inspection as "closed".
The company’s consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Shares of Zydus Lifesciences rose 0.71% to Rs 980 on the BSE.